The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | An insight into the Beat AML trial and the value of precision medicine
Amy Burd, PhD, Leukemia & Lymphoma Society, New York, NY, briefly outlines the structure and aims of the Beat AML trial (NCT03013998), a precision medicine trial evaluating patients with newly diagnosed acute myeloid leukemia (AML). Following this, Dr Burd further highlights how precision medicine has improved the outcomes of patients with newly diagnosed disease. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
